Table 2.
Clinical and imaging parameters in patients with a negative rebiopsy vs. patients with a positive rebiopsy
| Characteristics | Negative rebiopsy | Positive rebiopsy | P |
|---|---|---|---|
| Number of patients | 20 | 14 | - |
| Age (years) | 57 (54–63.5) | 61.5 (55.3–64.8) | 0.472 |
| Initial PSA (ng/mL) | 6.18 (4.85–8.08) | 5.09 (2.88–8.83) | 0.302 |
| Initial whole prostate volume (mL) | 57.5 (45–66.5) | 45.5 (33.5–61.8) | 0.132 |
| Initial PSA density (ng/mL2) | 0.116 (0.086–0.146) | 0.086 (0.063–0.214) | 0.270 |
| Follow-up PSA (ng/mL) | 7.04 (5.00–9.12) | 5.03 (2.85–9.55) | 0.241 |
| Follow-up whole prostate volume (mL) | 59.5 (50.8–84.0) | 48 (39.5–64.3) | 0.146 |
| Follow-up PSA density (ng/mL2) | 0.102 (0.079–0.155) | 0.106 (0.056–0.198) | 0.793 |
| Time interval between biopsies (months) | 14.5 (12.25–20.0) | 16.5 (15–25.3) | 0.105 |
| Initial DRE findings | |||
| Normal | 18 (90%) | 12 (86%) | 1.000 |
| Abnormal | 2 (10%) | 2 (14%) | |
| Follow-up DRE findings | |||
| Normal | 16 (80%) | 14 (100%) | 0.126 |
| Abnormal | 4 (20%) | 0 (0%) | |
| Number of lesions on initial MRI | |||
| 1 | 9 (45%) | 6 (43%) | 0.502 |
| 2 | 9 (45%) | 5 (36%) | |
| 3 | 1 (5%) | 3 (21%) | |
| 4 | 1 (5%) | 0 (0%) | |
| Index lesion diameter on initial MRI (mm) | 11 (8–14) | 1.1 (8–14) | 0.792 |
| Change in highest MRI suspicion level | |||
| Stable | 13 (65%) | 12 (86%) | 0.250 |
| Increase | 7 (35%) | 2 (14%) | |
| New lesions seen on follow-up MRI | |||
| No new lesion | 17 (85%) | 13 (93%) | 0.627 |
| New lesion | 3 (15%) | 1 (7%) | |
| History of prostate biopsy outside our institution | |||
| None | 5 (25%) | 2 (14%) | 0.004 |
| Prior negative | 10 (50%) | 1 (7%) | |
| Prior positive | 5 (25%) | 11 (79%) |
DRE, digital rectal examination; MRI, magnetic resonance imaging; PSA, prostate-specific antigen.
Data are given as median (interquartile range) or n (%).